Your Article Summary
See Latest ArticlesCourt Grants Teva Summary Judgment Of Non-Infringement On Eloxatin
Teva Pharmaceutical Industries, 06/19/09
Teva Pharmaceutical Industries Ltd. announced that the U.S. District Court for the District of New Jersey has granted summary judgment in Teva's favor on the issue of non-infringement with regard to Debiopharm's U.S. Patent No. 5,338,874. The patent is listed in the Orange Book for Sanofi-Aventis' chemotherapy medication Eloxatin, which had annual sales of approximately $1.3 billion in the United States for the twelve months that ended December 2008, based on IMS sales data.
Today in Regulatory Issues...keeping you current
Receive free subspecialty "5-minute updates" via email
Sixteen Fired for Records Snooping
HealthDataManagement, 12/09/09
Watson Files FDA Application for Generic Rozerem
Watson Pharmaceuticals, 12/07/09
Bristol-Myers Squibb And Pfizer Announce Plans To Submit Regulatory Filing For Apixaban In Europe
Bristol Myers-Squibb Company, 12/07/09